Results 2-5 cycles of chemotherapy were performed in all patients, the clinical benefit response (CBR) was 52%(41/79), PR was 25%(20/79), SD was 27%(21/79).

• 结果79例分别完成2-5周期联合化疗,其中完全缓解(CR)0例,部分缓解(PR)为25%25(20/79),稳定(SD)为27%25(21/79),临床受益反应(CBR)为52%25(41/79)。